Tatva Chintan Pharma Chem Submits FY25 Business Responsibility and Sustainability Report, Details ESG Initiatives
The submission of the Business Responsibility and Sustainability Report (BRSR) is a standard annual regulatory compliance. While it provides detailed insights into the company's ESG efforts and operations, including a minor environmental penalty, it does not present new information that would significantly alter the company's financial outlook or operational strategy in the short term.
The company submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2024-25, detailing ESG initiatives, goals, and performance. While it shows commitment to sustainability and positive progress in some areas, it also reported a penalty of ₹ 4.5 lakh for environmental violations, balancing the overall sentiment.
* Tatva Chintan Pharma Chem Limited (TATVA) has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2024-25, in compliance with Regulation 34(2)(f) of SEBI Listing Regulations. * The BRSR forms part of the Annual Report FY 2024-25 and is available on the company's website. * Key highlights from the report for FY 2024-25 include: * Financials: Paid-up Capital of ₹ 23.39 crore, Turnover of ₹ 366.41 crore, and Net Worth of ₹ 721.31 crore. * Business Activities: Specialty Chemicals account for 99.23% of turnover, with Structure Directing Agents, Phase Transfer Catalysts, and Pharmaceutical and Agrochemical Intermediates being major product lines. * Global Presence: Exports contributed 59.82% of total turnover, serving customers in 34 countries. * Workforce: The company has 349 permanent employees and 590 workers. * Sustainability Efforts: The company sources approximately 62.73% of its raw materials sustainably and operates Zero Liquid Discharge Units at its Ankleshwar manufacturing unit since January 2020. * ESG Goals & Performance (FY 2024-25): * Environment: Engaged with 31 raw material suppliers and 8 customers on sustainability initiatives; initiated multiple carbon intensity reduction efforts. * Social: Actively implemented CSR initiatives focused on education, rural development, environmental sustainability, and healthcare access; surpassed EHS training target with an average of 20 hours per employee. * Governance: Reported zero instances of corruption or bribery. * Grievances: The company received 1 shareholder complaint and 10 customer complaints during FY 2024-25, all of which were resolved. * Penalties: A penalty of ₹ 4.5 lakh was paid to the Gujarat Pollution Control Board for alleged violations of the Water (Prevention and Control of Pollution) Act, 1974. * Employee Well-being: 1.30% of the total revenue from operations was spent on employee and worker well-being measures. * Accessibility: The company's offices and manufacturing units are accessible to differently-abled employees and workers.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under sustainability. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.